NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $3.92 +0.07 (+1.82%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.91 -0.01 (-0.26%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IRWD alerts:Sign Up Key Stats Today's Range$3.80▼$3.9350-Day Range$3.04▼$4.8352-Week Range$0.55▼$5.78Volume1.94 million shsAverage Volume2.65 million shsMarket Capitalization$639.20 millionP/E Ratio6.53Dividend YieldN/APrice Target$6.23Consensus RatingHold Company Overview Ironwood Pharmaceuticals, Inc. is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S. markets under the brand name CONSTELLA. In addition to its marketed therapy, Ironwood maintains a diversified pipeline of clinical and preclinical programs targeting GI motility, inflammation and neurological conditions. Lead pipeline candidates include novel small molecules designed to modulate gut motility and secretions, as well as agents aimed at central nervous system targets to address pain and neurodegenerative disorders. The company leverages in-house research capabilities alongside external partnerships to advance its portfolio. Founded in 1998 as Microbia Biosciences, the business rebranded as Ironwood Pharmaceuticals in 2010 concurrent with its initial public offering. Headquartered in Cambridge, Massachusetts, Ironwood conducts research and development activities in the U.S. and collaborates with global pharmaceutical partners to extend its reach into European, Canadian and other international markets. Ironwood is led by President and Chief Executive Officer Peter Hecht, who brings extensive experience in both commercial operations and strategic development within the biopharmaceutical industry. Under his leadership, the company continues to pursue innovative therapies aimed at addressing unmet needs in GI health and related therapeutic areas.AI Generated. May Contain Errors. Read More Ironwood Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreIRWD MarketRank™: Ironwood Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 220th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 strong buy rating, 2 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialIronwood Pharmaceuticals has a consensus price target of $6.23, representing about 59.0% upside from its current price of $3.92.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to decrease in the coming year, from $0.88 to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is 6.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is 6.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.14.Read more about Ironwood Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.67% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 10.51, which indicates bearish sentiment.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 5.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.68 News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ironwood Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows12 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,528,940.00 in company stock.Percentage Held by Insiders9.30% of the stock of Ironwood Pharmaceuticals is held by insiders.Percentage Held by InstitutionsIronwood Pharmaceuticals has minimal institutional ownership at this time.Read more about Ironwood Pharmaceuticals' insider trading history. Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRWD Stock News HeadlinesIronwood Pharmaceuticals: A Contrarian Buy OpportunityMay 21 at 8:31 PM | seekingalpha.comIs Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?May 20 at 5:11 PM | insidermonkey.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Top 10 small‑cap value picks: lowest forward P/Es and strong profitabilityMay 18, 2026 | msn.comWall Street Zen Upgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to "Strong-Buy"May 17, 2026 | americanbankingnews.comIronwood Pharmaceuticals, Inc: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Recommendation of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.comSee More Headlines IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $3.37 at the beginning of 2026. Since then, IRWD shares have increased by 16.3% and is now trading at $3.92. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its earnings results on Thursday, May, 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by $0.01. The biotechnology company had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 39.65% and a net margin of 28.26%. Read the conference call transcript. When did Ironwood Pharmaceuticals IPO? Ironwood Pharmaceuticals (IRWD) raised $250 million in an initial public offering (IPO) on Wednesday, February 3rd 2010. The company issued 16,666,667 shares at a price of $14.00-$16.00 per share. Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' top institutional investors include Bank of America Corp DE (5.32%), Renaissance Technologies LLC (4.94%), Arrowstreet Capital Limited Partnership (2.08%) and Dimensional Fund Advisors LP (1.28%). Insiders that own company stock include Alexander J Denner, Thomas A Mccourt, Michael Shetzline, Sravan Kumar Emany, Andrew Davis, Minardo John, Ronald Silver, Julie Mchugh, Jon R Duane and Catherine Moukheibir. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/07/2026Today5/23/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 4 days ago, IRWD's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees220Year FoundedN/APrice Target and Rating Average Price Target for Ironwood Pharmaceuticals$6.23 High Price Target$10.00 Low Price Target$3.70 Potential Upside/Downside+59.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.60 Trailing P/E Ratio6.53 Forward P/E Ratio4.45 P/E GrowthN/ANet Income$24.02 million Net Margins28.26% Pretax Margin47.43% Return on Equity-39.65% Return on Assets26.54% Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.41 Sales & Book Value Annual Sales$296.15 million Price / Sales2.16 Cash Flow$0.26 per share Price / Cash Flow14.96 Book Value($1.33) per share Price / Book-2.95Miscellaneous Outstanding Shares163,060,000Free Float147,894,000Market Cap$639.20 million OptionableOptionable Beta0.29 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:IRWD) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
